Andrzej M Kierzek
Overview
Explore the profile of Andrzej M Kierzek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pawlowski T, Bokota G, Lazarou G, Kierzek A, Sroka J
Methods
. 2024 Jan;
223:118-126.
PMID: 38246229
Quantitative Systems Pharmacology (QSP) models are increasingly being applied for target discovery and dose selection in immuno-oncology (IO). Typical application involves virtual trial, a simulation of a virtual population of...
2.
Szatkowska R, Furmanek E, Kierzek A, Ludwig C, Adamczyk M
Int J Mol Sci
. 2023 Oct;
24(19).
PMID: 37834211
RNA polymerase III (RNAP III) holoenzyme activity and the processing of its products have been linked to several metabolic dysfunctions in lower and higher eukaryotes. Alterations in the activity of...
3.
Matthews R, Hollinshead D, Morrison D, van der Graaf P, Kierzek A
CPT Pharmacometrics Syst Pharmacol
. 2023 Jul;
12(7):889-903.
PMID: 37452454
Typical Quantitative Systems Pharmacology (QSP) workflows involve discussion of biology, supported by graphical diagrams, followed by construction of large Ordinary Differential Equation models. QSP Designer facilitates this process by providing...
4.
Franssen L, Swat M, Kierzek A, Rose R, van der Graaf P, Grimm H
CPT Pharmacometrics Syst Pharmacol
. 2022 Nov;
12(2):139-143.
PMID: 36418887
Immunogenicity against therapeutic proteins frequently causes attrition owing to its potential impact on pharmacokinetics, pharmacodynamics, efficacy, and safety. Predicting immunogenicity is complex because of its multifactorial drivers, including compound properties,...
5.
Desikan R, Padmanabhan P, Kierzek A, van der Graaf P
Int J Antimicrob Agents
. 2022 May;
60(1):106606.
PMID: 35588969
The COVID-19 pandemic has severely impacted health systems and economies worldwide. Significant global efforts are therefore ongoing to improve vaccine efficacies, optimize vaccine deployment, and develop new antiviral therapies to...
6.
Giorgi M, Desikan R, van der Graaf P, Kierzek A
CPT Pharmacometrics Syst Pharmacol
. 2021 Jul;
10(10):1130-1133.
PMID: 34331834
Optimal use and distribution of coronavirus disease 2019 (COVID-19) vaccines involves adjustments of dosing. Due to the rapidly evolving pandemic, such adjustments often need to be introduced before full efficacy...
7.
Chelliah V, Lazarou G, Bhatnagar S, Gibbs J, Nijsen M, Ray A, et al.
Clin Pharmacol Ther
. 2020 Jul;
109(3):605-618.
PMID: 32686076
Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno-oncology (IO) the aim is to direct the patient's...
8.
Lazarou G, Chelliah V, Small B, Walker M, van der Graaf P, Kierzek A
Clin Pharmacol Ther
. 2020 Jan;
107(4):858-870.
PMID: 31955413
Application of contemporary molecular biology techniques to clinical samples in oncology resulted in the accumulation of unprecedented experimental data. These "omics" data are mined for discovery of therapeutic target combinations...
9.
Shakhnovich V, Meibohm B, Rosenberg A, Kierzek A, Hasenkamp R, Funk R, et al.
Clin Transl Sci
. 2019 Nov;
13(2):219-223.
PMID: 31762152
No abstract available.
10.
Kierzek A, Hickling T, Figueroa I, Kalvass J, Nijsen M, Mohan K, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 Sep;
8(11):773-776.
PMID: 31529677
No abstract available.